1341 PharmaBio Delegate Booklet

1341 PharmaBio Delegate Booklet 28/11/07 14:41 Page 14
Sponsors
Almirall is an international pharmaceutical company that researches, develops, manufactures and commercialises
innovative proprietary drugs and those under licence in order to improve people’s health and wellbeing. Almirall focuses its
research resources in the areas of asthma, COPD (Chronic Obstructive Pulmonary Disease), psoriasis, rheumatoid arthritis
and multiple sclerosis.
Almirall is headquartered in Barcelona, Spain. The company employs approximately 3,000 people across the world, 30%
of whom are based outside Spain. The company markets its drugs in more than 80 countries including the US and Japan,
and has five affiliates in Europe (Germany, Belgium, France, Italy and Portugal) as well as one in Latin America (Mexico).
2006 IMS figures show that Almirall is the third largest pharmaceutical company in Spain (behind Pfizer and Novartis) and
is one of the top 40 largest pharmaceutical companies in Europe. The company was floated on the Spanish stock
exchange on 20 June 2007.
www.almirall.es
Warburg Pincus has been a leading private equity investor since 1971. The firm currently has more than $20 billion of
assets under management. Since inception, Warburg Pincus has invested more than $26 billion in more than 575
companies in 30 countries across a range of nine industry sectors. Healthcare is one of the firm’s core areas for
investment globally, with members of our healthcare team focused on biotechnology, specialty pharmaceuticals, medical
devices and healthcare services.
Our current European healthcare portfolio includes Archimedes Pharma, Eurand, Euromedic, ProStrakan and Tornier. The
firm has invested over $4 billion in healthcare globally, of which over $1 billion has been invested in Europe. For more
information, visit:
www.warburgpincus.com
–– 14 ––